A 32-year-old multigravida from Mumbai at 28 weeks of gestation is diagnosed with gestational diabetes after a 75 g OGTT (fasting 98 mg/dL, 1-hour 195 mg/dL, 2-hour 160 mg/dL). She has been counseled on medical nutrition therapy and started on a structured exercise program. At 32 weeks, repeat OGTT shows fasting glucose 110 mg/dL, 1-hour glucose 205 mg/dL, and 2-hour glucose 175 mg/dL. What is the most appropriate pharmacological agent to initiate?

Explanation

## Pharmacotherapy for GDM: First-Line Agents ### Glycemic Control Status **Key Point:** This patient has **failed lifestyle intervention**—glucose levels have worsened despite 4 weeks of MNT and exercise. Pharmacotherapy is now indicated. ### Comparison of Antidiabetic Agents in Pregnancy | Agent | Safety in Pregnancy | Mechanism | First-Line? | Notes | |---|---|---|---|---| | **Insulin** | Gold standard; no teratogenicity | Exogenous glucose control | YES | Does not cross placenta; proven safety record | | **Metformin** | Generally safe; emerging evidence | Reduces hepatic glucose production | YES (alternative) | Crosses placenta; long-term fetal data limited but reassuring | | **Gliclazide** | Avoided | Stimulates pancreatic β-cells | NO | Risk of neonatal hypoglycemia; crosses placenta | | **Pioglitazone** | Insufficient data; avoid | Insulin sensitizer | NO | Limited safety data; not recommended in pregnancy | | **GLP-1 agonists** | Insufficient data | Incretin mimetic | NO | Avoid; inadequate pregnancy data | ### First-Line Pharmacotherapy in GDM ```mermaid flowchart TD A[GDM: Lifestyle Intervention Failed]:::outcome --> B{Which Agent?}:::decision B -->|Preferred| C[Insulin]:::action B -->|Alternative| D[Metformin]:::action C --> E[NPH or Rapid-Acting Analogs]:::action D --> F[500 mg BD, titrate to 2000 mg/day]:::action E --> G[Achieve Target Fasting < 95, 2-hour < 120 mg/dL]:::action F --> G ``` **High-Yield:** **Insulin is the gold standard and first-line pharmacotherapy for GDM** because: 1. Does not cross the placenta 2. No teratogenic effects 3. Longest safety record in pregnancy 4. Rapidly achieves glycemic control **Clinical Pearl:** Metformin is an acceptable alternative in resource-limited settings or when patient refuses insulin, but insulin remains the preferred agent in high-income settings and for severe hyperglycemia. ### Why Not Gliclazide? - Sulfonylureas cross the placenta and stimulate fetal pancreatic β-cells, causing **neonatal hypoglycemia** and hyperinsulinemia. - Associated with increased perinatal mortality in some studies. - **Contraindicated in pregnancy.** ### Why Not Pioglitazone? - Insufficient safety data in pregnancy. - Thiazolidinediones are associated with fluid retention and weight gain, problematic in pregnancy. - Not recommended by major guidelines (ACOG, ICMR). ### Insulin Regimens in GDM - **NPH (Isophane):** Long-acting, safe, most commonly used. - **Rapid-acting analogs (Aspart, Lispro):** Mimic physiologic insulin secretion; safe in pregnancy. - **Avoid long-acting analogs (Glargine, Detemir):** Limited pregnancy data. [cite:ACOG Practice Bulletin 190, ICMR GDM Guidelines 2018, Endocrine Society Clinical Practice Guidelines]